Lobbyist information

Amount

John F.X. Heffernan	$130,000.00
Employed Terminated 01/01/2026

Total salaries paid:      $130,000.00

Client information

Amount

Acadia Pharmaceuticals Inc.	$30,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2026 Represent Acadia Pharmaceuticals Inc. on matters impacting public health, health insurance, patient access, biotechnology, and other related pharmaceutical issues.

Acuity Strategic Partners, LLC	$20,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2026 06/30/2026 Issues related to traumatic brain injury, education and prevention.

Amgen Inc.	$36,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2026 Legislation, regulations, and issues related to biopharmaceuticals, health care, drug pricing, transparency, business, and taxation.

Biotechnology Innovation Organization	$29,500.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2026 All Legislation and Executive Branch activities in the Commonwealth including, but not limited to, agriculture, health care, economic development, Medicaid, and other issues pertaining to biotechnology.

Massachusetts Biotechnology Council, Inc.

$60,000.00

Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2026 Any and all legislation, regulations and policies pertaining to the healthcare system before the legislature or executive branch, including the Offices of the Governor and Lt Governor and all executive offices and agencies of the Commonwealth, the Office of the Attorney General, the Center for Health Information and Analysis, the Health Policy Commission, the Office of Pharmaceutical Policy and Analysis, and the Massachusetts Life Sciences Center, and that concern (a) a biopharmaceutical company's ability to market or sell its products in all sectors and markets in the Commonwealth; (b) patient access to innovative medicines and therapies in the Commonwealth; (c) implementation of Chapter 224 the Acts of 2012 as amended; (d) health care insurance coverage; (e) drug research and development; (f) pharmaceutical recycling, disposal and green bio policies; (g) drug pricing and drug price transparency; (h) the prescribing, dispensing and monitoring of controlled substances; (i) matters before the Massachusetts Life Sciences Center; (j) taxation policies affecting the biopharmaceutical industry; (k) drug safety policies; (j) pharmacy benefit manager practices; (k) the federal 340B program; (l) MassHealth coverage and reimbursement policies; and (m) drug marketing and marketing expense disclosure policies.

NanoDx, Inc	$0.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2026 06/30/2026 Issues related to traumatic brain injury, education and prevention.

Pfizer Inc.	$12,000.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 03/01/2026 All matters affecting pharmaceutical manufacturing and healthcare

PTC Therapeutics, Inc.	$0.00
Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2026 Relationship building with members of the Massachusetts legislature to discuss rare diseases, patient access to therapies and companies' economic impact in Massachusetts.

UCB, Inc.

$31,050.00

Employed Terminated Details about your lobbyist or lobbyist entity's efforts 01/01/2026 Any issue that impacts a biopharmaceutical company's ability to market or sell its products in all sectors/markets in the Commonwealth; any laws or regulations that impose or levy taxes upon a biopharmaceutical company doing business in the Commonwealth; and, any laws or regulations which provided incentives or disincentives to biopharmaceutical companies conducting research in the Commonwealth

Total salaries received:      $218,550.00

Expenditures

Amount